Highlighted Article Flyer for the journal “Current Alzheimer Research”

CAR-Articles_14-12-Annalena Venneri

http://benthamscience.com/journals/current-alzheimer-research/

Highlighted Article Flyer for the journal “Current Alzheimer Research”

CAR-Articles_14-Daniel W. Nixon.

http://benthamscience.com/journals/current-alzheimer-research/

New Issue :: Current Alzheimer Research 14, Issue 3

Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer’s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ‘bird’s-eye view’ of the current state of Alzheimer’s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.

car

Articles from the journal Current Alzheimer Research 14, Issue 3:


                          For details on the articles, please visit this link :: http://bit.ly/2m2yOS4

Testimonial by Dr. Gjumrakch Aliev!

dr-gjumrakch-aliev

Contributed Article: “Nanotechnology For Alzheimer Disease”

Highlighted Article Flyer for the journal “Current Alzheimer Research”

car-articles_14-2017-nobuhiro-yuki

http://benthamscience.com/journals/current-alzheimer-research/

New Issue :: Current Alzheimer Research 14, Issue 2

Current Alzheimer Research publishes peer-reviewed frontier review, research, drug clinical trial studies and letter articles on all areas of Alzheimer’s disease. This multidisciplinary journal will help in understanding the neurobiology, genetics, pathogenesis, and treatment strategies of Alzheimer’s disease. The journal publishes objective reviews written by experts and leaders actively engaged in research using cellular, molecular, and animal models. The journal also covers original articles on recent research in fast emerging areas of molecular diagnostics, brain imaging, drug development and discovery, and clinical aspects of Alzheimer’s disease. Manuscripts are encouraged that relate to the synergistic mechanism of Alzheimer’s disease with other dementia and neurodegenerative disorders. Book reviews, meeting reports and letters-to-the-editor are also published. The journal is essential reading for researchers, educators and physicians with interest in age-related dementia and Alzheimer’s disease. Current Alzheimer Research provides a comprehensive ‘bird’s-eye view’ of the current state of Alzheimer’s research for neuroscientists, clinicians, health science planners, granting, caregivers and families of this devastating disease.

car

Articles from the journal Current Alzheimer Research 14, Issue 2:

                              For details on the articles, please visit this link :: http://bit.ly/2k70jHg

Highlighted Article Flyer for the journal “Current Alzheimer Research”

car-articles_14-12-2017-s-tiziano-gomiero

http://benthamscience.com/journals/current-alzheimer-research/

Editor’s Choice – “Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?”

Journal: Current Alzheimer Research

Author(s): Parul Bali, Debomoy K. Lahiri, Avijit Banik, Bimla Nehru and Akshay Anand

car

Abstract:

Alzheimer’s disease (AD) is one of the most common causes of dementia. Despite several decades of research in AD, there is no standard disease- modifying therapy available and currentlyapproved drugs provide only symptomatic relief. Stem cells hold immense potential to regenerate damaged tissues and are currently tested in some brain-related disorders, such as AD, amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). We review stem cell transplantation studies using preclinical and clinical tools. We describe different sources of stem cells used in various animal models and explaining the putative molecular mechanisms that can rescue neurodegenerative disorders. The clinical studies suggest safety, efficacy and translational potential of stem cell therapy. The therapeutic outcome of stem cell transplantation has been promising in many studies, but no unifying hypothesis can convincingly explain the underlying mechanism. Some studies have reported paracrine effects exerted by these stem cells via the release of neurotrophic factors, while other studies describe the immunomodulatory effects exerted by the transplanted cells. There are also reports which indicate that stem cell transplantation might result in endogenous cell proliferation or replacement of diseased cells. In animal models of AD, stem cell transplantation is also believed to increase expression of synaptic proteins.

Read more here: http://benthamscience.com/journals/current-alzheimer-research/volume/14/issue/2/page/208/

Press Release for EurekAlert! Mild cognitive impairment patients take about 3 medications for concomittant diseases

Researchers from 20 European centres of the European Alzheimer’s Disease Consortium (EADC) studied 880 Mild Cognitive Impairment (MCI) patients (375 males, 505 females) older than 55 years old and without obvious causes of cognitive impairment. MCI is considered to be an intermediate stage between normal age-related cognitive decline and dementia. A complete history was obtained for all patients. In addition, demographical data were collected and several factors were studied, including the types and dosages of the medications taken.

Dr Vasileios Papaliagkas, the corresponding author of the paper, pointed that the vast majority of MCI patients were taking at least one medication, whereas slightly less than half of the patients (40%) took at least 4 medications. The types of medications that were most often taken for concomitant diseases were cardiovascular drugs (62.0%), antidepressants (16.8%), sedatives (14.6%), thyroid drugs (10.0%) and anti-diabetic drugs (7.6%). Drugs with anticholinergic effects may affect cognition in the elderly and their simultaneous use might cause cognitive impairment and reduction in daily functioning activities. They should be given with caution and only with a doctor’s prescription and over the counter drugs should be avoided. The existence of medical co-morbidities does not appear to increase the risk of dementia progression. Female and less educated patients are more likely to take medications.

Reference: Tsolaki, M.; et al (2016). MCI Patients in Europe: Medication and Comorbidities. The DESCRIPA Study. Curr Alzheimer Res., DOI: 10.2174/1567205013666160603002704

For More information about the article, please visit: http://benthamscience.com/journals/current-alzheimer-research/volume/13/issue/12/page/1407/

Highlighted Article Flyer for the journal “Current Alzheimer Research”

car-articles_13-12-i-m-okun

http://benthamscience.com/journals/current-alzheimer-research/